Schaefer IM, Dal Cin P, Landry LM, Fletcher CDM, Hanna GJ, French CA
CIC-NUTM1 fusion: A case which expands the spectrum of NUT-rearranged epithelioid malignancies. Genes Chromosomes Cancer. 2018 09; 57(9):446-451.
CIC-NUTM1 fusion: A case which expands the spectrum of NUT-rearranged epithelioid malignancies.
Hanna GJ, Kofman ER, Shazib MA, Woo SB, Reardon B, Treister NS, Haddad RI, Cutler CS, Antin JH, Van Allen EM, Uppaluri R, Soiffer RJ
Integrated genomic characterization of oral carcinomas in post-hematopoietic stem cell transplantation survivors. Oral Oncol. 2018 06; 81:1-9.
Integrated genomic characterization of oral carcinomas in post-hematopoietic stem cell transplantation survivors.
Schoenfeld JD, Gjini E, Rodig SJ, Tishler RB, Rawal B, Catalano PJ, Uppaluri R, Haddad RI, Hanna GJ, Chau NG, Rabinowits G, Lorch J, Jo VY, Krane JF, Goguen LA, Annino DJ, Abdelrahman S, Lipschitz M, Margalit DN
International journal of radiation oncology, biology, physics
Evaluating the PD-1 Axis and Immune Effector Cell Infiltration in Oropharyngeal Squamous Cell Carcinoma. Int J Radiat Oncol Biol Phys. 2018 09 01; 102(1):137-145.
Evaluating the PD-1 Axis and Immune Effector Cell Infiltration in Oropharyngeal Squamous Cell Carcinoma.
Human papillomavirus and oropharyngeal cancer. Curr Probl Cancer. 2018 09; 42(5):466-475.
Human papillomavirus and oropharyngeal cancer.
Miao D, Margolis CA, Vokes NI, Liu D, Taylor-Weiner A, Wankowicz SM, Adeegbe D, Keliher D, Schilling B, Tracy A, Manos M, Chau NG, Hanna GJ, Polak P, Rodig SJ, Signoretti S, Sholl LM, Engelman JA, Getz G, Jänne PA, Haddad RI, Choueiri TK, Barbie DA, Haq R, Awad MM, Schadendorf D, Hodi FS, Bellmunt J, Wong KK, Hammerman P, Van Allen EM
Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. Nat Genet. 2018 09; 50(9):1271-1281.
Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors.
Hanna GJ, Kacew A, Chau NG, Shivdasani P, Lorch JH, Uppaluri R, Haddad RI, MacConaill LE
Improved outcomes in PI3K-pathway-altered metastatic HPV oropharyngeal cancer. JCI Insight. 2018 09 06; 3(17).
Improved outcomes in PI3K-pathway-altered metastatic HPV oropharyngeal cancer.
Sridharan V, Rahman RM, Huang RY, Chau NG, Lorch JH, Uppaluri R, Haddad RI, Hanna GJ, Schoenfeld JD
Radiologic predictors of immune checkpoint inhibitor response in advanced head and neck squamous cell carcinoma. Oral Oncol. 2018 10; 85:29-34.
Radiologic predictors of immune checkpoint inhibitor response in advanced head and neck squamous cell carcinoma.
Associate Professor of Otolaryngology Head and Neck Surgery
Harris EJ, Hanna GJ, Chau N, Rabinowits G, Haddad R, Margalit DN, Schoenfeld J, Tishler RB, Barletta JA, Nehs M, Janne P, Huang J, Groden P, Kacew A, Lorch J
Everolimus in Anaplastic Thyroid Cancer: A Case Series. Front Oncol. 2019; 9:106.
Everolimus in Anaplastic Thyroid Cancer: A Case Series.
Kacew AJ, Harris EJ, Lorch JH, Haddad RI, Chau NG, Rabinowits G, LeBoeuf NR, Schmults CD, Thakuria M, MacConaill LE, Hanna GJ
European journal of cancer (Oxford, England : 1990)
Chromosome 3q arm gain linked to immunotherapy response in advanced cutaneous squamous cell carcinoma. Eur J Cancer. 2019 05; 113:1-9.
Chromosome 3q arm gain linked to immunotherapy response in advanced cutaneous squamous cell carcinoma.
Margalit DN, Haddad RI, Tishler RB, Chau NG, Schoenfeld JD, Bakst RL, Misiukiewicz KJ, Gupta V, Posner M, Hanna GJ, Mahmood U, Rawal B, Catalano PJ, Rath L, Bacay A, McHugh P, Rabinowits G
A Phase 1 Study of Afatinib in Combination with Postoperative Radiation Therapy with and Without Weekly Docetaxel in Intermediate- and High-Risk Patients with Resected Squamous Cell Carcinoma of the Head and Neck. Int J Radiat Oncol Biol Phys. 2019 09 01; 105(1):132-139.
A Phase 1 Study of Afatinib in Combination with Postoperative Radiation Therapy with and Without Weekly Docetaxel in Intermediate- and High-Risk Patients with Resected Squamous Cell Carcinoma of the Head and Neck.
Corresponding Member of the Faculty of Neurosurgery
Associate Professor of Radiation Oncology
Charlotte F. and Irving W. Rabb Professor of Medicine
Villa A, Hanna GJ, Kacew A, Frustino J, Hammerman PS, Woo SB
Oral keratosis of unknown significance shares genomic overlap with oral dysplasia. Oral Dis. 2019 Oct; 25(7):1707-1714.
Oral keratosis of unknown significance shares genomic overlap with oral dysplasia.
Hanna GJ, Lau CJ, Mahmood U, Supplee JG, Mogili AR, Haddad RI, Jänne PA, Paweletz CP
Salivary HPV DNA informs locoregional disease status in advanced HPV-associated oropharyngeal cancer. Oral Oncol. 2019 08; 95:120-126.
Salivary HPV DNA informs locoregional disease status in advanced HPV-associated oropharyngeal cancer.
Mahal BA, Catalano PJ, Haddad RI, Hanna GJ, Kass JI, Schoenfeld JD, Tishler RB, Margalit DN
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
Incidence and Demographic Burden of HPV-Associated Oropharyngeal Head and Neck Cancers in the United States. Cancer Epidemiol Biomarkers Prev. 2019 10; 28(10):1660-1667.
Incidence and Demographic Burden of HPV-Associated Oropharyngeal Head and Neck Cancers in the United States.
Assistant Professor of Otolaryngology Head and Neck Surgery
Slevin MK, Wollison BM, Powers W, Burns RT, Patel N, Ducar MD, Starrett GJ, Garcia EP, Manning DK, Cheng J, Hanna GJ, Kaye KM, Van Hummelen P, Nag A, Thorner AR, DeCaprio JA, MacConaill LE
The Journal of molecular diagnostics : JMD
ViroPanel: Hybrid Capture and Massively Parallel Sequencing for Simultaneous Detection and Profiling of Oncogenic Virus Infection and Tumor Genome. J Mol Diagn. 2020 04; 22(4):476-487.
ViroPanel: Hybrid Capture and Massively Parallel Sequencing for Simultaneous Detection and Profiling of Oncogenic Virus Infection and Tumor Genome.
Kacew AJ, Harris EJ, Lorch JH, Schoenfeld JD, Margalit DN, Kass JI, Tishler RB, Haddad RI, Hanna GJ
Chemotherapy after immune checkpoint blockade in patients with recurrent, metastatic squamous cell carcinoma of the head and neck. Oral Oncol. 2020 06; 105:104676.
Chemotherapy after immune checkpoint blockade in patients with recurrent, metastatic squamous cell carcinoma of the head and neck.
Hanna GJ, Bae JE, Lorch JH, Schoenfeld JD, Margalit DN, Tishler RB, Haddad RI, Chau NG
Long-term outcomes and clinicogenomic correlates in recurrent, metastatic adenoid cystic carcinoma. Oral Oncol. 2020 07; 106:104690.
Long-term outcomes and clinicogenomic correlates in recurrent, metastatic adenoid cystic carcinoma.
Hanna GJ, Bae JE, Lorch JH, Haddad RI, Jo VY, Schoenfeld JD, Margalit DN, Tishler RB, Goguen LA, Annino DJ, Chau NG
The Benefits of Adjuvant Trastuzumab for HER-2-Positive Salivary Gland Cancers. Oncologist. 2020 07; 25(7):598-608.
The Benefits of Adjuvant Trastuzumab for HER-2-Positive Salivary Gland Cancers.
Hanna GJ, Guenette JP, Chau NG, Sayehli CM, Wilhelm C, Metcalf R, Wong DJ, Brose M, Razaq M, Pérez-Ruiz E, Cohen EEW, Aggarwal R, Scholz C, Gualberto A, Ho AL
Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer. Cancer. 2020 09 01; 126(17):3972-3981.
Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer.
Hanna GJ, Kacew AJ, Tanguturi AR, Grote HJ, Vergara V, Brunkhorst B, Rabinowits G, Thakuria M, LeBoeuf NR, Ihling C, DeCaprio JA, Lorch JH
Association of Programmed Death 1 Protein Ligand (PD-L1) Expression With Prognosis in Merkel Cell Carcinoma. Front Med (Lausanne). 2020; 7:198.
Association of Programmed Death 1 Protein Ligand (PD-L1) Expression With Prognosis in Merkel Cell Carcinoma.
Danesh MJ, Mulvaney PM, Murakami N, Riella LV, Silk AW, Hanna GJ, Schmults CD
Impact of corticosteroids on allograft protection in renal transplant patients receiving anti-PD-1 immunotherapy. Cancer Immunol Immunother. 2020 09; 69(9):1937-1941.
Impact of corticosteroids on allograft protection in renal transplant patients receiving anti-PD-1 immunotherapy.
Uppaluri R, Campbell KM, Egloff AM, Zolkind P, Skidmore ZL, Nussenbaum B, Paniello RC, Rich JT, Jackson R, Pipkorn P, Michel LS, Ley J, Oppelt P, Dunn GP, Barnell EK, Spies NC, Lin T, Li T, Mulder DT, Hanna Y, Cirlan I, Pugh TJ, Mudianto T, Riley R, Zhou L, Jo VY, Stachler MD, Hanna GJ, Kass J, Haddad R, Schoenfeld JD, Gjini E, Lako A, Thorstad W, Gay HA, Daly M, Rodig SJ, Hagemann IS, Kallogjeri D, Piccirillo JF, Chernock RD, Griffith M, Griffith OL, Adkins DR
Clinical cancer research : an official journal of the American Association for Cancer Research
Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial. Clin Cancer Res. 2020 10 01; 26(19):5140-5152.
Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial.
Arbab M, Chen YH, Criscitiello S, Glass J, Fugazzotto JA, Killoran JH, Hanna G, Lorch J, Haddad RI, Margalit DN, Tishler RB, Schoenfeld JD
Patient reported outcomes in patients with head and neck cancer treated with concurrent chemoradiation with weekly versus bolus cisplatin. Head Neck. 2020 12; 42(12):3670-3677.
Patient reported outcomes in patients with head and neck cancer treated with concurrent chemoradiation with weekly versus bolus cisplatin.
Mahmood U, Bang A, Chen YH, Mak RH, Lorch JH, Hanna GJ, Nishino M, Manuszak C, Thrash EM, Severgnini M, Sanborn M, Sridharan V, Margalit DN, Tishler RB, Busse PM, Willers H, Mamon HJ, Yoo HJ, Pai SI, Wirth LJ, Haddad RI, Chau NG, Schoenfeld JD
A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma. Int J Radiat Oncol Biol Phys. 2021 01 01; 109(1):134-144.
A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma.
Schoenfeld JD, Hanna GJ, Jo VY, Rawal B, Chen YH, Catalano PS, Lako A, Ciantra Z, Weirather JL, Criscitiello S, Luoma A, Chau N, Lorch J, Kass JI, Annino D, Goguen L, Desai A, Ross B, Shah HJ, Jacene HA, Margalit DN, Tishler RB, Wucherpfennig KW, Rodig SJ, Uppaluri R, Haddad RI
Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial. JAMA Oncol. 2020 10 01; 6(10):1563-1570.
Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial.
Hanna GJ, Ruiz ES, LeBoeuf NR, Thakuria M, Schmults CD, Decaprio JA, Silk AW
Real-world outcomes treating patients with advanced cutaneous squamous cell carcinoma with immune checkpoint inhibitors (CPI). Br J Cancer. 2020 11; 123(10):1535-1542.
Real-world outcomes treating patients with advanced cutaneous squamous cell carcinoma with immune checkpoint inhibitors (CPI).
Bharmal M, Nolte S, Lebbé C, Mortier L, Brohl AS, Fazio N, Grob JJ, Pusceddu S, Hanna GJ, Hassel JC, Kiecker F, Ellers-Lenz B, Bajars M, Güzel G, Nghiem P, Hunger M, Schlichting M, Henry-Szatkowski M, D'Angelo SP
Health-related quality of life trajectory of treatment-naive patients with Merkel cell carcinoma receiving avelumab. Future Oncol. 2020 Sep; 16(27):2089-2099.
Health-related quality of life trajectory of treatment-naive patients with Merkel cell carcinoma receiving avelumab.
Park SI, Guenette JP, Suh CH, Hanna GJ, Chung SR, Baek JH, Lee JH, Choi YJ
The diagnostic performance of CT and MRI for detecting extranodal extension in patients with head and neck squamous cell carcinoma: a systematic review and diagnostic meta-analysis. Eur Radiol. 2021 Apr; 31(4):2048-2061.
The diagnostic performance of CT and MRI for detecting extranodal extension in patients with head and neck squamous cell carcinoma: a systematic review and diagnostic meta-analysis.
Harris JA, Hunter WP, Hanna GJ, Treister NS, Menon RS
Rural patients with oral squamous cell carcinoma experience better prognosis and long-term survival. Oral Oncol. 2020 12; 111:105037.
Rural patients with oral squamous cell carcinoma experience better prognosis and long-term survival.
Hanna GJ, Rettig EM, Park JC, Varvares MA, Lorch JH, Margalit DN, Schoenfeld JD, Tishler RB, Goguen LA, Annino DJ, Haddad RI, Uppaluri R
Hospitalization rates and 30-day all-cause mortality among head and neck cancer patients and survivors with COVID-19. Oral Oncol. 2021 01; 112:105087.
Hospitalization rates and 30-day all-cause mortality among head and neck cancer patients and survivors with COVID-19.
Campbell BR, Chen Z, Faden DL, Agrawal N, Li RJ, Hanna GJ, Iyer NG, Boot A, Rozen SG, Vettore AL, Panda B, Krishnan NM, Pickering CR, Myers JN, Guo X, Lang Kuhs KA
The mutational landscape of early- and typical-onset oral tongue squamous cell carcinoma. Cancer. 2021 02 15; 127(4):544-553.
The mutational landscape of early- and typical-onset oral tongue squamous cell carcinoma.
Chipidza FE, Thakuria M, Schoenfeld JD, Silk AW, Catalano PJ, Yoon CH, Hanna GJ, DeCaprio JA, Tishler RB, Margalit DN
Journal of the American Academy of Dermatology
Association between treatment center experience and survival after diagnosis of stage I to III Merkel cell carcinoma treated with surgery with or without postoperative radiation therapy. J Am Acad Dermatol. 2021 Mar; 84(3):875-877.
Association between treatment center experience and survival after diagnosis of stage I to III Merkel cell carcinoma treated with surgery with or without postoperative radiation therapy.
Malekzadeh S, Hanna G, Wilson B, Pehlivanova M, Milmoe G
A model for training and evaluation of myringotomy and tube placement skills. Laryngoscope. 2011 Jul; 121(7):1410-5.
A model for training and evaluation of myringotomy and tube placement skills.
Cheng ML, Pectasides E, Hanna GJ, Parsons HA, Choudhury AD, Oxnard GR
Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions. CA Cancer J Clin. 2021 03; 71(2):176-190.
Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions.
Murakami N, Mulvaney P, Danesh M, Abudayyeh A, Diab A, Abdel-Wahab N, Abdelrahim M, Khairallah P, Shirazian S, Kukla A, Owoyemi IO, Alhamad T, Husami S, Menon M, Santeusanio A, Blosser CD, Zuniga SC, Soler MJ, Moreso F, Mithani Z, Ortiz-Melo D, Jaimes EA, Gutgarts V, Lum E, Danovitch GM, Cardarelli F, Drews RE, Bassil C, Swank JL, Westphal S, Mannon RB, Shirai K, Kitchlu A, Ong S, Machado SM, Mothi SS, Ott PA, Rahma O, Hodi FS, Sise ME, Gupta S, Leaf DE, Devoe CE, Wanchoo R, Nair VV, Schmults CD, Hanna GJ, Sprangers B, Riella LV, Jhaveri KD
A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant. Kidney Int. 2021 07; 100(1):196-205.
A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant.
Kacew AJ, Dharaneeswaran H, Starrett GJ, Thakuria M, LeBoeuf NR, Silk AW, DeCaprio JA, Hanna GJ
Predictors of immunotherapy benefit in Merkel cell carcinoma. Oncotarget. 2020 Nov 24; 11(47):4401-4410.
Predictors of immunotherapy benefit in Merkel cell carcinoma.
Harris EJ, Huang J, Carroll E, Lowe AC, Chau NG, Rabinowits G, Haddad R, Hanna GJ, Haddad T, Sanborn M, Kacew A, Lorch J
Laryngoscope investigative otolaryngology
Circulating tumor cell analysis in locally advanced and metastatic squamous cell carcinoma of the head and neck. Laryngoscope Investig Otolaryngol. 2020 Dec; 5(6):1063-1069.
Circulating tumor cell analysis in locally advanced and metastatic squamous cell carcinoma of the head and neck.
Correction: Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-unrelated Head and Neck Cancer: A Multicenter, Phase II Trial. Clin Cancer Res. 2021 Jan 01; 27(1):357.
Correction: Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-unrelated Head and Neck Cancer: A Multicenter, Phase II Trial.
Harris JA, Ritchie CA, Hanna GJ, McCain JP, Ji YD
Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
The Inequitable Global Burden of Lip and Oral Cancers: Widening Disparities Across Countries. J Oral Maxillofac Surg. 2021 06; 79(6):1364-1372.
The Inequitable Global Burden of Lip and Oral Cancers: Widening Disparities Across Countries.
Shi DD, Liu KX, Hacker F, Hanna GJ, Kwong RY, Cagney DN, Mak RH, Singer L
Development and Implementation of an Online Adaptive Stereotactic Body Radiation Therapy Workflow for Treatment of Intracardiac Metastasis. Pract Radiat Oncol. 2021 Jul-Aug; 11(4):e395-e401.
Development and Implementation of an Online Adaptive Stereotactic Body Radiation Therapy Workflow for Treatment of Intracardiac Metastasis.
Value and Unmet Needs in Non-Invasive Human Papillomavirus (HPV) Testing for Oropharyngeal Cancer. Cancers (Basel). 2021 Feb 02; 13(3).
Value and Unmet Needs in Non-Invasive Human Papillomavirus (HPV) Testing for Oropharyngeal Cancer.
Effects of racial residential segregation on oral squamous cell carcinoma prognosis and survival. Oral Oncol. 2021 08; 119:105364.
Effects of racial residential segregation on oral squamous cell carcinoma prognosis and survival.
Hanna GJ, ONeill A, Cutler JM, Flynn M, Vijaykumar T, Clark JR, Wirth LJ, Lorch JH, Park JC, Mito JK, Lohr JG, Kaufman J, Burr NS, Zon LI, Haddad RI
A phase II trial of all-trans retinoic acid (ATRA) in advanced adenoid cystic carcinoma. Oral Oncol. 2021 08; 119:105366.
A phase II trial of all-trans retinoic acid (ATRA) in advanced adenoid cystic carcinoma.
Klein BA, Alves FA, de Santana Rodrigues Velho J, Vacharotayangul P, Hanna GJ, LeBoeuf NR, Shazib MA, Villa A, Woo SB, Sroussi H, Sonis S, Treister NS
Oral manifestations of immune-related adverse events in cancer patients treated with immune checkpoint inhibitors. Oral Dis. 2022 Jan; 28(1):9-22.
Oral manifestations of immune-related adverse events in cancer patients treated with immune checkpoint inhibitors.
D'Angelo SP, Lebbé C, Mortier L, Brohl AS, Fazio N, Grob JJ, Prinzi N, Hanna GJ, Hassel JC, Kiecker F, Georges S, Ellers-Lenz B, Shah P, Güzel G, Nghiem P
First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study. J Immunother Cancer. 2021 07; 9(7).
First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study.
Harris JA, Huang K, Miloslavsky E, Hanna GJ
Sicca syndrome associated with immune checkpoint inhibitor therapy. Oral Dis. 2022 Nov; 28(8):2083-2092.
Sicca syndrome associated with immune checkpoint inhibitor therapy.
Hematology/oncology clinics of North America
Preface. Hematol Oncol Clin North Am. 2021 10; 35(5):xiii-xiv.
Hanna GJ, O'Neill A, Shin KY, Wong K, Jo VY, Quinn CT, Cutler JM, Flynn M, Lizotte PH, Annino DJ, Goguen LA, Kass JI, Rettig EM, Sethi RKV, Lorch JH, Schoenfeld JD, Margalit DN, Tishler RB, Everett PC, Desai AM, Cavanaugh ME, Paweletz CP, Egloff AM, Uppaluri R, Haddad RI
Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2022 02 01; 28(3):468-478.
Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck.
Tyan K, Bae JE, Lorch JH, Margalit DN, Tishler RB, Huynh MA, Jo VY, Haddad RI, Chau NG, Hanna GJ, Schoenfeld JD
Oligometastatic adenoid cystic carcinoma: Correlating tumor burden and time to treatment with outcomes. Head Neck. 2022 03; 44(3):722-734.
Oligometastatic adenoid cystic carcinoma: Correlating tumor burden and time to treatment with outcomes.
Alhousami T, Diny M, Ali F, Shin J, Kumar G, Kumar V, Campbell JD, Noonan V, Hanna GJ, Denis GV, Monti S, Kukuruzinska MA, Varelas X, Bais MV
Inhibition of LSD1 Attenuates Oral Cancer Development and Promotes Therapeutic Efficacy of Immune Checkpoint Blockade and YAP/TAZ Inhibition. Mol Cancer Res. 2022 05 04; 20(5):712-721.
Inhibition of LSD1 Attenuates Oral Cancer Development and Promotes Therapeutic Efficacy of Immune Checkpoint Blockade and YAP/TAZ Inhibition.
Arbab M, Chen YH, Tishler RB, Gunasti L, Glass J, Fugazzotto JA, Killoran JH, Sethi R, Rettig E, Annino D, Goguen L, Uppaluri R, Hsu C, Burke E, Hanna GJ, Lorch J, Haddad RI, Margalit DN, Schoenfeld JD
Association between radiation dose to organs at risk and acute patient reported outcome during radiation treatment for head and neck cancers. Head Neck. 2022 06; 44(6):1442-1452.
Association between radiation dose to organs at risk and acute patient reported outcome during radiation treatment for head and neck cancers.
Rettig EM, Faden DL, Sandhu S, Wong K, Faquin WC, Warinner C, Stephens P, Kumar S, Kuperwasser C, Richmon JD, Uppaluri R, Varvares M, Sethi R, Hanna GJ, Sroussi H
Detection of circulating tumor human papillomavirus DNA before diagnosis of HPV-positive head and neck cancer. Int J Cancer. 2022 10 01; 151(7):1081-1085.
Detection of circulating tumor human papillomavirus DNA before diagnosis of HPV-positive head and neck cancer.
French CA, Cheng ML, Hanna GJ, DuBois SG, Chau NG, Hann CL, Storck S, Salgia R, Trucco M, Tseng J, Stathis A, Piekarz R, Lauer UM, Massard C, Bennett K, Coker S, Tontsch-Grunt U, Sos ML, Liao S, Wu CJ, Polyak K, Piha-Paul SA, Shapiro GI
Report of the First International Symposium on NUT Carcinoma. Clin Cancer Res. 2022 06 13; 28(12):2493-2505.
Report of the First International Symposium on NUT Carcinoma.
Liu KX, Milligan MG, Schoenfeld JD, Tishler RB, Ng AK, Devlin PM, Fite E, Rabinowits G, Hanna GJ, Silk AW, Yoon CH, Thakuria M, Margalit DN
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Characterization of clinical outcomes after shorter course hypofractionated and standard-course radiotherapy for stage I-III curatively-treated Merkel cell carcinoma. Radiother Oncol. 2022 08; 173:32-40.
Characterization of clinical outcomes after shorter course hypofractionated and standard-course radiotherapy for stage I-III curatively-treated Merkel cell carcinoma.
Berger BM, Hanna GJ, Posner MR, Genden EM, Lautersztain J, Naber SP, Del Vecchio Fitz C, Kuperwasser C
Detection of Occult Recurrence Using Circulating Tumor Tissue Modified Viral HPV DNA among Patients Treated for HPV-Driven Oropharyngeal Carcinoma. Clin Cancer Res. 2022 10 03; 28(19):4292-4301.
Detection of Occult Recurrence Using Circulating Tumor Tissue Modified Viral HPV DNA among Patients Treated for HPV-Driven Oropharyngeal Carcinoma.
Harris JA, Ottaviani G, Treister NS, Hanna GJ
An Overview of Clinical Oncology and Impact on Oral Health. Front Oral Health. 2022; 3:874332.
An Overview of Clinical Oncology and Impact on Oral Health.
Rettig EM, Wang AA, Tran NA, Carey E, Dey T, Schoenfeld JD, Sehgal K, Guenette JP, Margalit DN, Sethi R, Uppaluri R, Tishler RB, Annino DJ, Goguen LA, Jo VY, Haddad RI, Hanna GJ
JAMA otolaryngology-- head & neck surgery
Association of Pretreatment Circulating Tumor Tissue-Modified Viral HPV DNA With Clinicopathologic Factors in HPV-Positive Oropharyngeal Cancer. JAMA Otolaryngol Head Neck Surg. 2022 12 01; 148(12):1120-1130.
Association of Pretreatment Circulating Tumor Tissue-Modified Viral HPV DNA With Clinicopathologic Factors in HPV-Positive Oropharyngeal Cancer.
Steeghs N, Hansen AR, Hanna GJ, Garralda E, Park H, Strauss J, Adam M, Campbell G, Carver J, Easton R, Mays K, Skrdla P, Struemper H, Washburn ML, Matheny C, Piha-Paul SA
Manufacturing-dependent change in biological activity of the TLR4 agonist GSK1795091 and implications for lipid A analog development. Clin Transl Sci. 2022 11; 15(11):2625-2639.
Manufacturing-dependent change in biological activity of the TLR4 agonist GSK1795091 and implications for lipid A analog development.
Systemic and Targeted Therapies in Adenoid Cystic Carcinoma. Curr Treat Options Oncol. 2023 01; 24(1):45-60.
Systemic and Targeted Therapies in Adenoid Cystic Carcinoma.
Tran NA, Palotai M, Hanna GJ, Schoenfeld JD, Bay CP, Rettig EM, Bunch PM, Juliano AF, Kelly HR, Suh CH, Zander DA, Morales Pinzon A, Kann BH, Huang RY, Haddad RI, Guttmann CRG, Guenette JP
Diagnostic performance of computed tomography features in detecting oropharyngeal squamous cell carcinoma extranodal extension. Eur Radiol. 2023 May; 33(5):3693-3703.
Diagnostic performance of computed tomography features in detecting oropharyngeal squamous cell carcinoma extranodal extension.
Hanna GJ, Villa A, Mistry N, Jia Y, Quinn CT, Turner MM, Felt KD, Pfaff K, Haddad RI, Uppaluri R, Rodig SJ, Woo SB, Egloff AM, Hodi FS
Comprehensive Immunoprofiling of High-Risk Oral Proliferative and Localized Leukoplakia. Cancer Res Commun. 2021 10; 1(1):30-40.
Comprehensive Immunoprofiling of High-Risk Oral Proliferative and Localized Leukoplakia.
Correction: Comprehensive Immunoprofiling of High-risk Oral Proliferative and Localized Leukoplakia. Cancer Res Commun. 2022 May; 2(5):390.
Correction: Comprehensive Immunoprofiling of High-risk Oral Proliferative and Localized Leukoplakia.
Rettig EM, Waterboer T, Sim E, Faden DL, Butt J, Hanna GJ, Del Vecchio Fitz C, Kuperwasser C, Sroussi H
Relationship of HPV16 E6 seropositivity with circulating tumor tissue modified HPV16 DNA before head and neck cancer diagnosis. Oral Oncol. 2023 06; 141:106417.
Relationship of HPV16 E6 seropositivity with circulating tumor tissue modified HPV16 DNA before head and neck cancer diagnosis.
Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors. Hematol Oncol Clin North Am. 2023 12; 37(6):1149-1168.
Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors.
Black CM, Hanna GJ, Wang L, Ramakrishnan K, Goto D, Turzhitsky V, Hair GM
Real-world treatment patterns and outcomes among individuals receiving first-line pembrolizumab therapy for recurrent/metastatic head and neck squamous cell carcinoma. Front Oncol. 2023; 13:1160144.
Real-world treatment patterns and outcomes among individuals receiving first-line pembrolizumab therapy for recurrent/metastatic head and neck squamous cell carcinoma.
McInnis C, Bhatia S, Vijaykumar B, Tian Q, Sun Y, Leistritz-Edwards D, Quinn CT, Uppaluri R, Egloff AM, Srinivasan L, Pregibon DC, Coyle AJ, Hanna GJ
Identification of HPV16 E1 and E2-specific T cells in the oropharyngeal cancer tumor microenvironment. J Immunother Cancer. 2023 03; 11(3).
Identification of HPV16 E1 and E2-specific T cells in the oropharyngeal cancer tumor microenvironment.
Smith AE, Chan S, Wang Z, McCloskey A, Reilly Q, Wang JZ, Patel HV, Koshizuka K, Soifer HS, Kessler L, Dayoub A, Villaflor V, Adkins DR, Bruce JY, Ho AL, Perez CA, Hanna GJ, Gascó Hernández A, Saunders A, Dale S, Gutkind JS, Burrows F, Malik S
Tipifarnib Potentiates the Antitumor Effects of PI3Ka Inhibition in PIK3CA- and HRAS-Dysregulated HNSCC via Convergent Inhibition of mTOR Activity. Cancer Res. 2023 10 02; 83(19):3252-3263.
Tipifarnib Potentiates the Antitumor Effects of PI3Ka Inhibition in PIK3CA- and HRAS-Dysregulated HNSCC via Convergent Inhibition of mTOR Activity.
Steuer CE, Hanna GJ, Viswanathan K, Bates JE, Kaka AS, Schmitt NC, Ho AL, Saba NF
The evolving landscape of salivary gland tumors. CA Cancer J Clin. 2023 Nov-Dec; 73(6):597-619.
The evolving landscape of salivary gland tumors.
Hanna GJ, Patel N, Tedla SG, Baugnon KL, Aiken A, Agrawal N
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
Personalizing Surveillance in Head and Neck Cancer. Am Soc Clin Oncol Educ Book. 2023 01; 43:e389718.
Personalizing Surveillance in Head and Neck Cancer.
Oliveira G, Egloff AM, Afeyan AB, Wolff JO, Zeng Z, Chernock RD, Zhou L, Messier C, Lizotte P, Pfaff KL, Stromhaug K, Penter L, Haddad RI, Hanna GJ, Schoenfeld JD, Goguen LA, Annino DJ, Jo V, Oppelt P, Pipkorn P, Jackson R, Puram SV, Paniello RC, Rich JT, Webb J, Zevallos JP, Mansour M, Fu J, Dunn GP, Rodig SJ, Ley J, Morris LGT, Dunn L, Paweletz CP, Kallogjeri D, Piccirillo JF, Adkins DR, Wu CJ, Uppaluri R
Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti-PD-1 in head and neck cancer. Sci Immunol. 2023 09 08; 8(87):eadf4968.
Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti-PD-1 in head and neck cancer.
Hanna GJ, Ahn MJ, Muzaffar J, Keam B, Bowles DW, Wong DJ, Ho AL, Kim SB, Worden F, Yun T, Meng X, Van Tornout JM, Conlan MG, Kang H
A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma. Clin Cancer Res. 2023 11 14; 29(22):4555-4563.
A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma.
Corrigendum: Real-world treatment patterns and outcomes among individuals receiving first-line pembrolizumab therapy for recurrent/metastatic head and neck squamous cell carcinoma. Front Oncol. 2023; 13:1240947.
Corrigendum: Real-world treatment patterns and outcomes among individuals receiving first-line pembrolizumab therapy for recurrent/metastatic head and neck squamous cell carcinoma.
Hanna GJ, Stathis A, Lopez-Miranda E, Racca F, Quon D, Leyvraz S, Hess D, Keam B, Rodon J, Ahn MJ, Kim HR, Schneeweiss A, Ribera JM, DeAngelo D, Perez Garcia JM, Cortes J, Schönborn-Kellenberger O, Weber D, Pisa P, Bauer M, Beni L, Bobadilla M, Lehal R, Vigolo M, Vogl FD, Garralda E
A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors. Cancer Res Commun. 2023 09 14; 3(9):1853-1861.
A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors.
Hanna GJ, Roof SA, Jabalee J, Rettig EM, Ferrandino R, Chen S, Posner MR, Misiukiewicz KJ, Genden EM, Chai RL, Sims J, Thrash E, Stern SJ, Kalman NS, Yarlagadda S, Raben A, Clements L, Mendelsohn A, Kaczmar JM, Pandey Y, Bhayani M, Gupta P, Kuperwasser C, Del Vecchio Fitz C, Berger BM
Negative Predictive Value of Circulating Tumor Tissue Modified Viral (TTMV)-HPV DNA for HPV-driven Oropharyngeal Cancer Surveillance. Clin Cancer Res. 2023 10 13; 29(20):4306-4313.
Negative Predictive Value of Circulating Tumor Tissue Modified Viral (TTMV)-HPV DNA for HPV-driven Oropharyngeal Cancer Surveillance.
Kim EY, Ruiz ES, Hanna GJ, Thakuria M, Silk AW
Sensitivity of personalized circulating tumor DNA assay in advanced cutaneous squamous cell carcinoma. J Am Acad Dermatol. 2024 02; 90(2):427-429.
Sensitivity of personalized circulating tumor DNA assay in advanced cutaneous squamous cell carcinoma.
Hanna GJ, Villa A, Nandi SP, Shi R, ONeill A, Liu M, Quinn CT, Treister NS, Sroussi HY, Vacharotayangul P, Goguen LA, Annino DJ, Rettig EM, Jo VY, Wong KS, Lizotte P, Paweletz CP, Uppaluri R, Haddad RI, Cohen EEW, Alexandrov LB, William WN, Lippman SM, Woo SB
Nivolumab for Patients With High-Risk Oral Leukoplakia: A Nonrandomized Controlled Trial. JAMA Oncol. 2024 01 01; 10(1):32-41.
Nivolumab for Patients With High-Risk Oral Leukoplakia: A Nonrandomized Controlled Trial.
Immunotherapy for head and neck cancer: where do we go from here? Immunotherapy. 2023 12; 15(18):1497-1500.
Immunotherapy for head and neck cancer: where do we go from here?
Ferrarotto R, Swiecicki PL, Zandberg DP, Baiocchi RA, Wesolowski R, Rodriguez CP, McKean M, Kang H, Monga V, Nath R, Palmisiano N, Babbar N, Sun W, Hanna GJ
PRT543, a protein arginine methyltransferase 5 inhibitor, in patients with advanced adenoid cystic carcinoma: An open-label, phase I dose-expansion study. Oral Oncol. 2024 Feb; 149:106634.
PRT543, a protein arginine methyltransferase 5 inhibitor, in patients with advanced adenoid cystic carcinoma: An open-label, phase I dose-expansion study.
Luo J, Sanchez M, Lee E, Hertzler H, Luong N, Mazzola E, Finstein B, Tamen R, Brisbane G, Nguyen T, Paik PK, Chaft JE, Cheng ML, Khalil H, Piha-Paul SA, Sholl LM, Nishino M, Jänne PA, DuBois SG, Hanna GJ, Shapiro GI, French CA
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Initial Chemotherapy for Locally Advanced and Metastatic NUT Carcinoma. J Thorac Oncol. 2024 May; 19(5):829-838.
Initial Chemotherapy for Locally Advanced and Metastatic NUT Carcinoma.
Hanna GJ, Chang SS, Siddiqui F, Bain PA, Takiar V, Ward MC, Shukla ME, Hu KS, Robbins J, Witek ME, Bakst R, Chandra RA, Galloway T, Margalit DN
Imaging and Biomarker Surveillance for Head and Neck Squamous Cell Carcinoma: A Systematic Review and American Radium Society Appropriate Use Criteria Statement. Int J Radiat Oncol Biol Phys. 2024 Jul 01; 119(3):786-802.
Imaging and Biomarker Surveillance for Head and Neck Squamous Cell Carcinoma: A Systematic Review and American Radium Society Appropriate Use Criteria Statement.
Hanna GJ, Dharanesswaran H, Giobbie-Hurder A, Harran JJ, Liao Z, Pai L, Tchekmedyian V, Ruiz ES, Waldman AH, Schmults CD, Riella LV, Lizotte P, Paweletz CP, Chandraker AK, Murakami N, Silk AW
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma. J Clin Oncol. 2024 Mar 20; 42(9):1021-1030.
Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma.
Huffman BM, Singh H, Ali LR, Horick N, Wang SJ, Hoffman MT, Metayer KA, Murray S, Bird A, Abrams TA, Biller LH, Chan JA, Meyerhardt JA, McCleary NJ, Goessling W, Patel AK, Wisch JS, Yurgelun MB, Mouw K, Reardon B, Van Allen EM, Zerillo JA, Clark JW, Parikh A, Mayer RJ, Schlechter B, Ng K, Kumar S, Del Vecchio Fitz C, Kuperwasser C, Hanna GJ, Coveler AL, Rubinson DA, Welsh EL, Pfaff K, Rodig S, Dougan SK, Cleary JM
Biomarkers of pembrolizumab efficacy in advanced anal squamous cell carcinoma: analysis of a phase II clinical trial and a cohort of long-term responders. J Immunother Cancer. 2024 01 25; 12(1).
Biomarkers of pembrolizumab efficacy in advanced anal squamous cell carcinoma: analysis of a phase II clinical trial and a cohort of long-term responders.
Hanna GJ, Grover P, Elliott A, McGrath J, Xiu J, Sukari A, Johnson JM, Wise-Draper T
Molecular Profiling and the Impact of Treatment on Outcomes in Adenoid Cystic Carcinoma Type I and II. Clin Cancer Res. 2024 May 15; 30(10):2225-2232.
Molecular Profiling and the Impact of Treatment on Outcomes in Adenoid Cystic Carcinoma Type I and II.
Black CM, Zheng D, Hair GM, Ai L, Wang L, Goto D, Lerman N, Bidadi B, Hanna GJ
Real-world use of first-line pembrolizumab + platinum + taxane combination regimens in recurrent / metastatic head and neck squamous cell carcinoma. Front Oncol. 2024; 14:1348045.
Real-world use of first-line pembrolizumab + platinum + taxane combination regimens in recurrent / metastatic head and neck squamous cell carcinoma.
Kim EY, Ruiz ES, DeSimone MS, Shalhout SZ, Hanna GJ, Miller DM, Schmults C, Rettig EM, Foreman RK, Sethi R, Thakuria M, Silk AW
Neoadjuvant-Intent Immunotherapy in Advanced, Resectable Cutaneous Squamous Cell Carcinoma. JAMA Otolaryngol Head Neck Surg. 2024 05 01; 150(5):414-420.
Neoadjuvant-Intent Immunotherapy in Advanced, Resectable Cutaneous Squamous Cell Carcinoma.
Cancer Precursor Syndromes and Their Detection in the Head and Neck. Hematol Oncol Clin North Am. 2024 08; 38(4):813-830.
Cancer Precursor Syndromes and Their Detection in the Head and Neck.
Hanna GJ, Dennis MJ, Scarfo N, Mullin MS, Sethi RKV, Sehgal K, Annino DJ, Goguen LA, Haddad RI, Tishler RB, Margalit DN, Uppaluri R, Schoenfeld JD, Rettig EM
Personalized ctDNA for Monitoring Disease Status in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2024 Aug 01; 30(15):3329-3336.
Personalized ctDNA for Monitoring Disease Status in Head and Neck Squamous Cell Carcinoma.
Roof SA, Jabalee J, Rettig EM, Chennareddy S, Ferrandino RM, Chen S, Posner MR, Genden EM, Chai RL, Sims J, Thrash E, Stern SJ, Kalman NS, Yarlagadda S, Raben A, Clements L, Mendelsohn A, Kaczmar JM, Pandey Y, Bhayani M, Del Vecchio Fitz C, Hanna GJ
Utility of TTMV-HPV DNA in resolving indeterminate findings during oropharyngeal cancer surveillance. Oral Oncol. 2024 Aug; 155:106874.
Utility of TTMV-HPV DNA in resolving indeterminate findings during oropharyngeal cancer surveillance.
Hanna GJ, Jabalee J, Lukens JN, Sun L, Rettig EM, Ferrandino R, Posner MR, Misiukiewicz KJ, Routman DM, Van Abel KM, Del Vecchio Fitz C, Roof SA
Circulating tumor tissue modified viral (TTMV)-HPV DNA in Recurrent, metastatic HPV-driven oropharyngeal cancer. Oral Oncol. 2024 Nov; 158:107002.
Circulating tumor tissue modified viral (TTMV)-HPV DNA in Recurrent, metastatic HPV-driven oropharyngeal cancer.
Sun L, Cohen RB, D'Avella CA, Singh AP, Schoenfeld JD, Hanna GJ
Overall Survival, Treatment Duration, and Rechallenge Outcomes With ICI Therapy for Recurrent or Metastatic HNSCC. JAMA Netw Open. 2024 08 01; 7(8):e2428526.
Overall Survival, Treatment Duration, and Rechallenge Outcomes With ICI Therapy for Recurrent or Metastatic HNSCC.
Archives of otolaryngology--head & neck surgery
Pathology quiz case 2. Solitary fibrous tumor (SFT) of the hypopharynx. Arch Otolaryngol Head Neck Surg. 2011 Aug; 137(8):830; author reply 833-4.
Pathology quiz case 2. Solitary fibrous tumor (SFT) of the hypopharynx.
Dennis MJ, Pavlick DC, Kacew A, Wotman M, MacConaill LE, Jones SM, Pfaff KL, Rodig SJ, Eacker S, Malig M, Reister E, Piccioni D, Kesari S, Sehgal K, Haddad RI, Cohen E, Posner MR, Deichaite I, Hanna GJ
Low PD-L1 expression, MAP2K2 alterations, and enriched HPV gene signatures characterize brain metastases in head and neck squamous cell carcinoma. J Transl Med. 2024 Oct 22; 22(1):960.
Low PD-L1 expression, MAP2K2 alterations, and enriched HPV gene signatures characterize brain metastases in head and neck squamous cell carcinoma.
Hanna GJ, Oakley LB, Shi R, ONeill A, Shin KY, Scarfo N, Sehgal K, Dennis MJ, Quinn N, Jo VY, Wong K, Shvyrkova A, Kushnarev V, Shanthappa BU, Tkachuk A, Kryukov K, Sarachakov A, Svekolkin V, Lennerz J, Waters S, Haddad RI
Duvelisib with Docetaxel for Patients with Anti-PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2025 Feb 17; 31(4):619-627.
Duvelisib with Docetaxel for Patients with Anti-PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma.
Rettig EM, Schoenfeld JD, Miller J, Sargent B, Carey E, Margalit DN, Sehgal K, Sethi RKV, Uppaluri R, Tishler RB, Goguen LA, Annino DJ, Sim ES, Jo VY, Wong KS, Guenette JP, Haddad RI, Hanna GJ
A Prospective Trial of Biomarker-Guided Surveillance for HPV-Positive Oropharynx Cancer Using Plasma Tumor Tissue-Modified Viral HPV DNA. Clin Cancer Res. 2025 May 01; 31(9):1605-1614.
A Prospective Trial of Biomarker-Guided Surveillance for HPV-Positive Oropharynx Cancer Using Plasma Tumor Tissue-Modified Viral HPV DNA.
Hanna GJ, Zheng D, Gao W, Hair GM, Ai L, Song Y, Lerman N, Bidadi B, Zion A, Zou L, Tang Y, Wang L, Merchant S, Black CM
PD-L1 testing patterns in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in the U.S. Oral Oncol. 2025 Feb; 161:107146.
PD-L1 testing patterns in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in the U.S.
Zhao M, Schoenfeld JD, Egloff AM, Hanna GJ, Haddad RI, Adkins DR, Uppaluri R
T cell dynamics with neoadjuvant immunotherapy in head and neck cancer. Nat Rev Clin Oncol. 2025 Feb; 22(2):83-94.
T cell dynamics with neoadjuvant immunotherapy in head and neck cancer.
Naing A, Papadopoulos KP, Pishvaian MJ, Rahma O, Hanna GJ, Garralda E, Saavedra O, Gogov S, Kallender H, Cheng L, Smith M, Chen X, Kuriakose E, Bauer T
First-in-human phase 1 study of the arginase inhibitor INCB001158 alone or combined with pembrolizumab in patients with advanced or metastatic solid tumours. BMJ Oncol. 2024; 3(1):e000249.
First-in-human phase 1 study of the arginase inhibitor INCB001158 alone or combined with pembrolizumab in patients with advanced or metastatic solid tumours.
Luo J, Bishop JA, DuBois SG, Hanna GJ, Sholl LM, Stelow EB, Thompson LDR, Shapiro GI, French CA
Hiding in plain sight: NUT carcinoma is an unrecognized subtype of squamous cell carcinoma of the lungs and head and neck. Nat Rev Clin Oncol. 2025 Apr; 22(4):292-306.
Hiding in plain sight: NUT carcinoma is an unrecognized subtype of squamous cell carcinoma of the lungs and head and neck.
Shapiro RM, Sheffer M, Booker MA, Tolstorukov MY, Birch GC, Sade-Feldman M, Fang J, Li S, Lu W, Ansuinelli M, Dulery R, Tarannum M, Baginska J, Dwivedi N, Kothari A, Penter L, Abdulhamid YZ, Kaplan IE, Khanhlinh D, Uppaluri R, Redd RA, Nikiforow S, Koreth J, Ritz J, Wu CJ, Soiffer RJ, Hanna GJ, Romee R
First-in-human evaluation of memory-like NK cells with an IL-15 super-agonist and CTLA-4 blockade in advanced head and neck cancer. J Hematol Oncol. 2025 Feb 14; 18(1):17.
First-in-human evaluation of memory-like NK cells with an IL-15 super-agonist and CTLA-4 blockade in advanced head and neck cancer.
Witek ME, Ward MC, Bakst R, Chandra RA, Chang SS, Choi KY, Galloway T, Hanna GJ, Hu KS, Robbins J, Shukla ME, Siddiqui F, Takiar V, Walker GV, Fu Y, Margalit DN
Paranasal Sinus and Nasal Cavity Cancers: Systematic Review and Executive Summary of the American Radium Society Appropriate Use Criteria. Head Neck. 2025 Aug; 47(8):2073-2091.
Paranasal Sinus and Nasal Cavity Cancers: Systematic Review and Executive Summary of the American Radium Society Appropriate Use Criteria.
Bakhtiar M, Ye Z, Schoenfeld JD, Mohammadi H, Guenette JP, Rettig EM, Hanna GJ, Kann BH
Artificial Intelligence Measured Tumor Burden and Pre-Treatment Circulating Tumor DNA in Human Papilloma Virus-Associated Oropharynx Cancer. Head Neck. 2025 Oct; 47(10):2641-2649.
Artificial Intelligence Measured Tumor Burden and Pre-Treatment Circulating Tumor DNA in Human Papilloma Virus-Associated Oropharynx Cancer.
Sim ES, Nguyen HCB, Hanna GJ, Uppaluri R
Current Progress and Future Directions of Immunotherapy in Head and Neck Squamous Cell Carcinoma: A Narrative Review. JAMA Otolaryngol Head Neck Surg. 2025 May 01; 151(5):521-528.
Current Progress and Future Directions of Immunotherapy in Head and Neck Squamous Cell Carcinoma: A Narrative Review.
Hanna GJ, Cote GM, Chugh R, Thomas JS, Malhotra J, Cutler RE, Hood T, Carvajal LA, Olek EA, Villalona-Calero MA
Safety and Efficacy of a Selective Inhibitor of Cyclin-dependent Kinase 9 (KB-0742) in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma. Cancer Res Commun. 2025 May 01; 5(5):767-773.
Safety and Efficacy of a Selective Inhibitor of Cyclin-dependent Kinase 9 (KB-0742) in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma.
Jiménez-Labaig P, Lorini L, Gurizzan C, Kinloch E, Burton S, Forster MD, Metcalf R, Ferrarotto R, Bossi P, O Leary B, Hanna G, Felip E, Garcia IB, Harrington KJ
Clinical trials for patients with salivary gland cancers: A systematic review of worldwide registers and an evaluation of current challenges. Crit Rev Oncol Hematol. 2025 Jul; 211:104747.
Clinical trials for patients with salivary gland cancers: A systematic review of worldwide registers and an evaluation of current challenges.
Corrigendum to "PD-L1 testing patterns in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in the U.S." [Oral Oncol. 161 (2025) 107146]. Oral Oncol. 2025 Oct; 169:107292.
Corrigendum to "PD-L1 testing patterns in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in the U.S." [Oral Oncol. 161 (2025) 107146].
The Challenge and Promise of Circulating Tumor HPV DNA for Minimal Residual Disease Detection-Catching the Unseen. JAMA Otolaryngol Head Neck Surg. 2025 Jul 01; 151(7):672-674.
The Challenge and Promise of Circulating Tumor HPV DNA for Minimal Residual Disease Detection-Catching the Unseen.
Professor of Otolaryngology Head and Neck Surgery
So J, Droznin AD, Tiwari P, Chen YH, Chau NG, Margalit DN, Tishler RB, Hanna GJ, Mak RH, Fitzgerald KJ, Sehgal K, Li S, Gunasti L, Kim E, Minken J, Baginska J, Nau A, Diaz IG, Shim B, Janes JT, Uppaluri R, Haddad RI, Livak KJ, Schoenfeld JD
Stereotactic Body Radiation Therapy With Pembrolizumab in Programmed Cell Death Protein 1 Inhibitor-Refractory Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Phase 2 Trial. Int J Radiat Oncol Biol Phys. 2026 May 01; 125(1):64-77.
Stereotactic Body Radiation Therapy With Pembrolizumab in Programmed Cell Death Protein 1 Inhibitor-Refractory Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Phase 2 Trial.
Goodnight BL, Hanna GJ, Zheng D, Habila M, Cassese M, Fortman A, Walbert H, Sieling F, Black CM
Access to head and neck cancer specialists: a geospatial analysis of U.S. travel time. Front Oncol. 2025; 15:1521370.
Access to head and neck cancer specialists: a geospatial analysis of U.S. travel time.
Pettas E, Woo SB, Margalit DN, Tishler RB, Haddad RI, Hanna GJ, Treister NS
Lenalidomide for the Treatment of Chronic Oral Mucositis and Soft Tissue Necrosis After Radiation Therapy. Pract Radiat Oncol. 2026 Feb 18.
Lenalidomide for the Treatment of Chronic Oral Mucositis and Soft Tissue Necrosis After Radiation Therapy.
Pandrangi VC, Liao JJ, de Almeida JR, El-Sayed IH, Hanna G, Su SY, Tsang R, Won TB, Witterick I, Choby G, Kuan EC, Geltzeiler M
Current Trends in the Management of Recurrent Nasopharyngeal Carcinoma. Head Neck. 2025 Sep; 47(9):2611-2621.
Current Trends in the Management of Recurrent Nasopharyngeal Carcinoma.
Milhem MM, Wise-Draper TM, Chandra S, Hanna GJ, Laux DE, Medina TM, Ansstas G, Daud A, Kelly CM, O'Day SJ, Perez CA, Wong MK, Friedlander PA, Kristedja TS, Burgess MA, Cowey CL, Hanks BA, Weight RM, Daniel WL, Feltner DE, Mix S, Sindelar L, Bexon AS, Bexon MF, Michel RE, Bhatia S
Phase 1b/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumors. J Immunother Cancer. 2025 Jul 25; 13(7).
Phase 1b/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumors.
Ward MC, Kang JJ, Saba NF, Campbell SR, Akhave NS, Chang SS, Spencer SA, Spreafico A, Hanna GJ, Yom SS, Heron DE
Journal of the National Cancer Institute
Salvage of locoregionally recurrent head and neck cancer: an NRG oncology working group review. J Natl Cancer Inst. 2026 Feb 02.
Salvage of locoregionally recurrent head and neck cancer: an NRG oncology working group review.
London NR, Hanna GJ, Akhave NS, Choby G, Devriese LA, Ferrand FR, Gallia GL, Li L, Moya-Plana A, Rehman U, Takeda T, Thariat J, Woods RSR, Verillaud B, Lechner M
International network for sinonasal cancer research (INSICA): a collaborative group to advance research and clinical trials for rare sinonasal malignancies. J Natl Cancer Inst. 2025 Dec 17.
International network for sinonasal cancer research (INSICA): a collaborative group to advance research and clinical trials for rare sinonasal malignancies.
Hanna GJ, Scarfo N, Shin KY, O'Neill A, Bedard V, Dennis MJ, Sehgal K, Jo VY, Wong K, Ugolkov A, Mazar A, Haddad RI
Elraglusib, a Glycogen Synthase Kinase 3ß Inhibitor, plus Chemotherapy with or without Immunotherapy in Patients with Recurrent, Metastatic Salivary Gland Carcinoma. Clin Cancer Res. 2026 Jan 06; 32(1):83-93.
Elraglusib, a Glycogen Synthase Kinase 3ß Inhibitor, plus Chemotherapy with or without Immunotherapy in Patients with Recurrent, Metastatic Salivary Gland Carcinoma.
Williams MM, Hanna GJ, Sethi RK, Rettig EM
Outcomes of oropharyngeal squamous cell carcinoma among patients with lymphoproliferative disorders. Oral Oncol. 2025 Nov; 170:107761.
Outcomes of oropharyngeal squamous cell carcinoma among patients with lymphoproliferative disorders.
Hanna GJ, Zamulko OY, Grover P, Adkins DR, Oppelt PJ, Romano AE, Lehn MA, Bachmann LM, Wikenheiser-Brokamp KA, Lemmon CA, Forsythe AJ, Allen CL, Pan J, Rai SN, El-Gamal D, Wise-Draper TM
Amivantamab for Recurrent or Metastatic Adenoid Cystic Carcinoma: A Phase 2 Nonrandomized Clinical Trial. JAMA Otolaryngol Head Neck Surg. 2026 Apr 01; 152(4):376-383.
Amivantamab for Recurrent or Metastatic Adenoid Cystic Carcinoma: A Phase 2 Nonrandomized Clinical Trial.
Wagle N, Grabiner BC, Van Allen EM, Amin-Mansour A, Taylor-Weiner A, Rosenberg M, Gray N, Barletta JA, Guo Y, Swanson SJ, Ruan DT, Hanna GJ, Haddad RI, Getz G, Kwiatkowski DJ, Carter SL, Sabatini DM, Jänne PA, Garraway LA, Lorch JH
Response and acquired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med. 2014 Oct 09; 371(15):1426-33.
Response and acquired resistance to everolimus in anaplastic thyroid cancer.
Li YY, Hanna GJ, Laga AC, Haddad RI, Lorch JH, Hammerman PS
Genomic analysis of metastatic cutaneous squamous cell carcinoma. Clin Cancer Res. 2015 Mar 15; 21(6):1447-56.
Genomic analysis of metastatic cutaneous squamous cell carcinoma.
Lorch JH, Hanna GJ, Posner MR, O'Neill A, Thotakura VL, Limaye SA, Rabinowits G, Sher DJ, Tishler RB, Haddad RI
Human papillomavirus and induction chemotherapy versus concurrent chemoradiotherapy in locally advanced oropharyngeal cancer: The Dana Farber Experience. Head Neck. 2016 04; 38 Suppl 1:E1618-24.
Human papillomavirus and induction chemotherapy versus concurrent chemoradiotherapy in locally advanced oropharyngeal cancer: The Dana Farber Experience.
Gibson WJ, Ruan DT, Paulson VA, Barletta JA, Hanna GJ, Kraft S, Calles A, Nehs MA, Moore FD, Taylor-Weiner A, Wala JA, Zack TI, Lee TC, Fennessy FM, Alexander EK, Thomas T, Janne PA, Garraway LA, Carter SL, Beroukhim R, Lorch JH, Van Allen EM
Genomic Heterogeneity and Exceptional Response to Dual Pathway Inhibition in Anaplastic Thyroid Cancer. Clin Cancer Res. 2017 May 01; 23(9):2367-2373.
Genomic Heterogeneity and Exceptional Response to Dual Pathway Inhibition in Anaplastic Thyroid Cancer.
Sultan A, Hanna GJ, Margalit DN, Chau N, Goguen LA, Marty FM, Rabinowits G, Schoenfeld JD, Sonis ST, Thomas T, Tishler RB, Treister NS, Villa A, Woo SB, Haddad R, Mawardi H
The Use of Hyperbaric Oxygen for the Prevention and Management of Osteoradionecrosis of the Jaw: A Dana-Farber/Brigham and Women's Cancer Center Multidisciplinary Guideline. Oncologist. 2017 03; 22(3):343-350.
The Use of Hyperbaric Oxygen for the Prevention and Management of Osteoradionecrosis of the Jaw: A Dana-Farber/Brigham and Women's Cancer Center Multidisciplinary Guideline.
Hanna GJ, Liu H, Jones RE, Bacay AF, Lizotte PH, Ivanova EV, Bittinger MA, Cavanaugh ME, Rode AJ, Schoenfeld JD, Chau NG, Haddad RI, Lorch JH, Wong KK, Uppaluri R, Hammerman PS
Defining an inflamed tumor immunophenotype in recurrent, metastatic squamous cell carcinoma of the head and neck. Oral Oncol. 2017 04; 67:61-69.
Defining an inflamed tumor immunophenotype in recurrent, metastatic squamous cell carcinoma of the head and neck.
Hanna GJ, Sridharan V, Margalit DN, La Follette SK, Chau NG, Rabinowits G, Lorch JH, Haddad RI, Tishler RB, Anderson KS, Schoenfeld JD
Cancer biomarkers : section A of Disease markers
Salivary and serum HPV antibody levels before and after definitive treatment in patients with oropharyngeal squamous cell carcinoma. Cancer Biomark. 2017; 19(2):129-136.
Salivary and serum HPV antibody levels before and after definitive treatment in patients with oropharyngeal squamous cell carcinoma.
Hanna GJ, Adkins DR, Zolkind P, Uppaluri R
Rationale for neoadjuvant immunotherapy in head and neck squamous cell carcinoma. Oral Oncol. 2017 10; 73:65-69.
Rationale for neoadjuvant immunotherapy in head and neck squamous cell carcinoma.
Jenkins RW, Aref AR, Lizotte PH, Ivanova E, Stinson S, Zhou CW, Bowden M, Deng J, Liu H, Miao D, He MX, Walker W, Zhang G, Tian T, Cheng C, Wei Z, Palakurthi S, Bittinger M, Vitzthum H, Kim JW, Merlino A, Quinn M, Venkataramani C, Kaplan JA, Portell A, Gokhale PC, Phillips B, Smart A, Rotem A, Jones RE, Keogh L, Anguiano M, Stapleton L, Jia Z, Barzily-Rokni M, Cañadas I, Thai TC, Hammond MR, Vlahos R, Wang ES, Zhang H, Li S, Hanna GJ, Huang W, Hoang MP, Piris A, Eliane JP, Stemmer-Rachamimov AO, Cameron L, Su MJ, Shah P, Izar B, Thakuria M, LeBoeuf NR, Rabinowits G, Gunda V, Parangi S, Cleary JM, Miller BC, Kitajima S, Thummalapalli R, Miao B, Barbie TU, Sivathanu V, Wong J, Richards WG, Bueno R, Yoon CH, Miret J, Herlyn M, Garraway LA, Van Allen EM, Freeman GJ, Kirschmeier PT, Lorch JH, Ott PA, Hodi FS, Flaherty KT, Kamm RD, Boland GM, Wong KK, Dornan D, Paweletz CP, Barbie DA
Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discov. 2018 02; 8(2):196-215.
Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids.
The Use of Hyperbaric Oxygen for the Prevention and Management of Osteoradionecrosis of the Jaw: A Dana-Farber/Brigham and Women's Cancer Center Multidisciplinary Guideline. Oncologist. 2017 11; 22(11):1413.
Hanna G, Lin SJ, Wertheimer MD, Sharma R
Unresolved, atraumatic breast hematoma: post-irradiation or secondary breast angiosarcoma. Breast Dis. 2011; 33(3):139-42.
Unresolved, atraumatic breast hematoma: post-irradiation or secondary breast angiosarcoma.
Hanna GJ, Busaidy NL, Chau NG, Wirth LJ, Barletta JA, Calles A, Haddad RI, Kraft S, Cabanillas ME, Rabinowits G, O'Neill A, Limaye SA, Alexander EK, Moore FD, Misiwkeiwicz K, Thomas T, Nehs M, Marqusee E, Lee SL, Jänne PA, Lorch JH
Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study. Clin Cancer Res. 2018 04 01; 24(7):1546-1553.
Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study.
Hanna GJ, Lizotte P, Cavanaugh M, Kuo FC, Shivdasani P, Frieden A, Chau NG, Schoenfeld JD, Lorch JH, Uppaluri R, MacConaill LE, Haddad RI
Frameshift events predict anti-PD-1/L1 response in head and neck cancer. JCI Insight. 2018 02 22; 3(4).
Frameshift events predict anti-PD-1/L1 response in head and neck cancer.
Induction chemotherapy for locoregionally advanced head and neck cancer: past, present, future? Oncologist. 2013; 18(3):288-93.
Induction chemotherapy for locoregionally advanced head and neck cancer: past, present, future?